

Cancer Pain Market Size to Reach ~USD 40.53 Billion by 2034, Growing at 5.8% CAGR

The global cancer pain market size was approximately USD 25.82 billion in 2024 and is projected to reach around USD 40.53 billion by 2034

PUNE, MAHARASHTRA, INDIA, September 5, 2025 /EINPresswire.com/ -- The global Cancer Pain Market Size, covering pharmacologic and nonpharmacologic solutions that improve quality of life for oncology patients, was valued at ~USD 25.82 billion in



2024 and is projected to reach ~USD 40.53 billion by 2034, expanding at a compound annual growth rate (CAGR) of about 5.8% between 2025 and 2034. Rising cancer prevalence, advances in palliative care, and expanded access to novel analgesics are key factors propelling steady market growth worldwide.



global cancer pain market size was approximately USD 25.82 billion in 2024 and is projected to reach around USD 40.53 billion by 2034, growth rate (CAGR) of approximately 5.80% between 2025 and 2034."

Deepak Rupnar

Access key findings and insights from our Report in this sample -

https://www.zionmarketresearch.com/sample/cancer-painmarket

Executive Summary

Market Size: USD 25.82 B (2024)

USD 40.53 B (2034)

Growth Rate: ~5.8% CAGR (2025-2034)

Key Insights:

As per the analysis shared by our research analyst, the global cancer pain market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2025-2034)

In terms of revenue, the global cancer pain market size was valued at around USD 25.82 billion in 2024 and is projected to reach USD 40.53 billion by 2034.

The cancer pain market is projected to grow significantly owing to mounting demand for palliative care, growing cancer incidences worldwide, and government funding support and initiatives.

Based on drug class, the opioids segment is expected to lead the market, while the NSAIDs segment is expected to grow considerably. Based on the indication, the lung cancer segment is the largest, while the breast cancer segment is projected to experience substantial revenue growth over the forecast period.

Based on route of administration, the oral segment is expected to lead the market, while the parenteral segment is expected to grow considerably. Based on end-users, the hospitals segment is the largest, while the



homecare segment is projected to experience substantial revenue growth over the forecast period.

Based on the distribution channel, the hospital pharmacy segment is expected to lead the market, followed by the retail pharmacy segment.

Based on region, North America is projected to dominate the global market during the estimated period, followed by Europe.

Key Drivers: Increasing oncology caseload, supportive government & NGO initiatives, improved opioid stewardship, integration of non-drug therapies

Restraints: Opioid regulatory barriers, risk of misuse, limited pain care access in low-income regions

Opportunities: Non-opioid innovations, digital symptom monitoring, precision dosing, and emerging-market palliative care infrastructure

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.zionmarketresearch.com/custom/9689

Market Scope

Cancer pain is managed through opioid and non-opioid pharmacotherapy, adjuvant drugs, interventional procedures, and supportive therapies. Effective pain control remains central to improving patient function, adherence to cancer therapy, and end-of-life care outcomes.

Market Segmentation
By Drug Class
Opioids (morphine, oxycodone, fentanyl, others)
Non-Opioid Analgesics (NSAIDs, acetaminophen)
Adjuvant Analgesics (antidepressants, anticonvulsants, corticosteroids)

By Route of Administration
Oral
Parenteral (IV, SC, IM)
Transdermal / Patch
Others (Intrathecal, Rectal, Sublingual)

By Pain Type Neuropathic Pain Nociceptive / Somatic Pain Mixed / Breakthrough Pain

By End User Hospitals & Oncology Clinics Ambulatory Care & Palliative Centers Homecare Settings

By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Regional Highlights

North America

2024 Status: Largest market with robust oncology infrastructure, established opioid stewardship, and palliative care programs.

Outlook: Steady growth via biosimilars, long-acting opioid formulations, and home-based digital pain monitoring.

Europe

2024 Status: Mature market with standardized cancer pain guidelines and public reimbursement.

Outlook: Expansion of multimodal analgesia, growing hospice care funding, and opioid-sparing regimens.

Asia Pacific

2024 Status: Increasing cancer incidence; improving drug access in Japan, China, and India. Outlook: Fastest CAGR; national palliative initiatives and WHO-backed opioid access reforms support rapid uptake.

Latin America

2024 Status: Gradual progress; Brazil, Mexico, and Argentina lead adoption. Outlook: Policy reforms on opioid availability, NGO engagement, and training of oncology specialists.

Middle East & Africa

2024 Status: Underpenetrated but improving via UAE, Saudi Arabia oncology centers. Outlook: Long-term growth as governments invest in palliative care training and drug distribution.

Market Drivers

Rising Global Cancer Burden: More patients requiring long-term symptom relief. Integration of Palliative Care: Early palliative involvement improves survival and comfort. Pharmaceutical Innovation: Extended-release opioids, abuse-deterrent formulations, novel adjuvants.

Awareness Campaigns: Physician and patient education reduces undertreatment. Digital Health: Apps and remote monitoring streamline dosing and adherence.

Restraints & Challenges

Opioid Regulations & Stigma: Strict control reduces access in several countries. Addiction & Diversion Risks: Heightened scrutiny affects prescribing. Limited Pain Expertise: Insufficient training in some emerging healthcare systems.

Opportunities

Non-Opioid & Combination Therapies: Cannabinoid research, nerve-targeted analgesics, genebased pain modulation.

Al-Enabled Precision Dosing: Personalized regimens improving safety and efficacy. Expansion of Home Palliative Services: Chronic pain management outside hospitals. Emerging-Market Access Programs: WHO-supported opioid supply chain and training.

Inquiry For Buying-https://www.zionmarketresearch.com/inquiry/cancer-pain-market

Competitive Landscape — Key Players

Purdue Pharma / Mundipharma Eli Lilly & Co. Pfizer Inc.

Teva Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals
Mallinckrodt Pharmaceuticals
Janssen Pharmaceuticals (Johnson & Johnson)
Grünenthal GmbH

AstraZeneca PLC Hospira (Pfizer)

Others: Regional generic manufacturers and specialty palliative care drug developers

Market moderately fragmented; innovation centers on opioid-sparing regimens, abuse-deterrent formulations, and integrated digital monitoring.

Strategic Recommendations

Broaden Opioid Access Responsibly: Balance regulation and patient need via training & digital oversight.

Advance Multimodal Analgesia: Combine pharmacologic and interventional strategies for better outcomes.

Invest in Education & Guidelines: Standardize cancer pain protocols in emerging markets. Leverage Tele-Palliative Solutions: Remote symptom tracking reduces hospital burden. R&D in Non-Opioid Modalities: Novel pathways to address neuropathic and refractory pain.

Outlook to 2034

The cancer pain management market is on a steady growth trajectory, driven by increasing oncology prevalence, patient-centric care models, and non-opioid innovation. By 2034, revenues are expected to exceed USD 40.53 billion, with Asia Pacific showing the fastest expansion while North America and Europe maintain leadership through advanced pain care frameworks.

Browse Other Related Research Reports from Zion Market Research-

First Aid Training Market By Course Level (CPR & AED Training, Wilderness First Aid, Advanced First Aid, and Basic First Aid), By Industry (Construction, Education, Healthcare, and Manufacturing), By Course Provider (Private Training Companies, National Safety Council, American Heart Association, and Red Cross), By Training Method (Virtual, In-Person, and Combination), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/first-aid-training-market

Hematology Analyzers and Reagents Market By Product Type (Reagents and Instruments), By End-User (Diagnostics Labs, Research Institutions, and Hospitals), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/hematology-analyzers-reagents-market

U.S. Alginate Dressings Market By Type (Non-Antimicrobial and Antimicrobial), By Application (Acute Wounds, Diabetic Foot Ulcers, Surgical & Traumatic Wounds, Pressure Ulcers, Burns, and Venous Leg Ulcers), By End-Use (Hospitals, Home HealthCare, and Specialty Clinics), and By Region - Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/us-alginate-dressings-market

US Tissue Diagnostics Market By Technology (Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology & Workflow, and Anatomic Pathology), By Application (Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer, Gastric Cancer, and Other Cancers), and By Country-State Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/us-tissue-diagnostics-market

India AI in Healthcare Market By Service Type (Hospitals, Ambulatory Service Providers, Clinics, and Specialty Centers), By Treatment Type (Therapeutic, Diagnostic, Surgical, Nutritional, Palliative, Preventive, and Interventional), and By Region - Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/india-ai-in-healthcare-market

Idiopathic Pulmonary Fibrosis Market By Treatment Centers (Hospitals, Ambulatory Centers, Specialty Facilities, and Others), By Drug Type (Pirfenidone and Nintedanib), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/idiopathic-pulmonary-fibrosis-market

India Dietary Supplements Market By Product Type (Vitamin & Mineral Dietary Supplements, Herbal Dietary Supplements, Protein Dietary Supplements, and Others), By Form (Tablets, Capsules, Powders, Liquids, Soft Gels, and Gel Caps), By Distribution Channel (Pharmacies & Drug Stores, Supermarkets & Hypermarkets, Online Channels, and Others), By Application (Additional Supplements, Medicinal Supplement, and Sports Nutrition), By End-Use (Infant, Children, Adults, Pregnant Women, and Old-Aged), and By Region- Country and State Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2024 - 2032-https://www.zionmarketresearch.com/report/india-dietary-supplements-market

Deepak Rupnar
Zion Market Research
+1 855-465-4651
richard@zionmarketresearch.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/846330405 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.